PRe-surgery drug combo for lung cancer with genetic changes
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether giving a combination of an immunotherapy drug (adebrelimab) and chemotherapy before surgery can shrink tumors better in lung cancer that has certain genetic changes. The hope is that this pre-surgery treatment will improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Are 18 years old or older
- Have lung cancer that can be removed by surgery
- Your cancer has certain genetic mutations (like EGFR or ALK)
- You are in generally good health (able to take care of yourself)
- You have not had chemotherapy or other cancer treatment for this cancer before
- Do not have diseases like lupus or rheumatoid arthritis
- Can avoid pregnancy during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
This trial tests a new drug combined with other treatments for people with lung cancer that can be removed by surgery. It aims to see if the treatment shrinks tumors before surgery and improves outcomes.
This trial tests whether combining an immunotherapy drug (adebrelimab or retlirafusp alfa) with another drug (recaticimab) and chemotherapy helps shrink lung cancer before surgery. The goal is to see if this approach improves outcomes for people with resectable non-small cell lung cancer.
This trial tests whether combining two drugs, adebrelimab (an immunotherapy that helps your immune system fight cancer) and apatinib (a targeted therapy that blocks blood supply to tumors), before surgery can improve outcomes for people with early-stage non-small cell lung cancer. The goal is to shrink the tumor and make surgery more effective.
This trial tests a combination of medicines given before surgery and immunotherapy after surgery for resectable non-small cell lung cancer (NSCLC). It aims to shrink the tumor before the operation and reduce the risk of cancer coming back after surgery.
This trial tests a new drug, SHR-A2102, combined with other treatments for people with non-small cell lung cancer that can be removed with surgery. It aims to improve outcomes by using multiple therapies together.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.